Physicochemical characteristics, cytotoxicity, and antioxidant activity of three lipid nanoparticulate formulations of alpha-lipoic acid

AAPS PharmSciTech

Volumn 10, Issue 1, 2009, Pages 227-234

  Ruktanonchai, Uracha ^a   Bejrapha, Piyawan ^a   Sakulkhu, Usawadee ^a   Opanasopit, Praneet ^b   Bunyapraphatsara, Nuntavan ^c   Junyaprasert, Varaporn ^c   Puttipipatkhachorn, Satit ^c  

^a NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^b SILPAKORN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Alpha lipoic acid; Antioxidation activity; Nanoemulsion; Nanostructure lipid carriers; Solid lipid nanoparticles

Indexed keywords

DRUG CARRIER; NANOSTRUCTURE LPID CARRIER; POLOXAMER; SOLID LIPID NANOPARTICLE; THIOCTIC ACID; UNCLASSIFIED DRUG; ANTIOXIDANT; HYDROGEN PEROXIDE; LIPID; NANOPARTICLE; OXIDIZING AGENT;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CRYO SCANNING ELECTRON MICROSCOPY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; HUMAN; HUMAN CELL; IN VITRO STUDY; NANOEMULSION; PARTICLE SIZE; PROLONGE RELEASE FORMULATION; SCANNING ELECTRON MICROSCOPY; SKIN FIBROBLAST; ZETA POTENTIAL; CELL CULTURE; CHEMICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIFFERENTIAL SCANNING CALORIMETRY; DOSE RESPONSE; DRUG EFFECT; EMULSION; FIBROBLAST; KINETICS; METABOLISM; METHODOLOGY; OXIDATIVE STRESS; PATHOLOGY; PHARMACEUTICS; SOLUBILITY; SURFACE PROPERTY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTIOXIDANTS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL SURVIVAL; CELLS, CULTURED; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; EMULSIONS; FIBROBLASTS; HUMANS; HYDROGEN PEROXIDE; KINETICS; LIPIDS; MODELS, CHEMICAL; NANOPARTICLES; OXIDANTS; OXIDATIVE STRESS; PARTICLE SIZE; SOLUBILITY; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; THIOCTIC ACID;

EID: 67549102925     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9193-6     Document Type: Article

References (36)

1. U. Cakatay, A. Telci, R. Kayali, A. Sivas, and T. Akcay. Effect of lipoic acid supplementation on oxidative protein damage in the streptozotocin-diabetic rat. Res. Exp. Med. (Berl). 199:243-251 (2000).
2. Y. Dincer, A. Telci, R. Kayal, C. Yilmazia, U. Cakatay, and T. Akcay. Effect of a-lipoic acid on lipid peroxidation and antioxidant enzyme activities in diabetic rats. Clin. Exp. Pharmacol. Physiol. 29:281-284 (2002).
3. M. A. Lovell, C. Xie, S. Xiong, and W. R. Markesbery. Protection against amyloid b peptide and iron/hydrogen peroxide toxicity by a-lipoic acid. J. Alzheimer Dis. 5:229-239 (2003).
4. G. H. Marracci, G. P. McKeon, W. E. Marquardt, R. W. Winter, M. K. Riscoe, and D. N. Bourdette. α-Lipoic acid inhibits human T cell migration: Implications for multiple sclerosis. J. Neurosci. Res. 78:362-370 (2004).
5. A. R. Smith, S. V. Shenvi, M. Widlansky, J. H. Suh, and T. M. Hagen. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr. Med. Chem. 11:1135-1146 (2004).
6. A. Baur, T. Harrer, M. Peukert, G. Jahn, J. R. Kalden, and B. Fleckenstein. Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication. J. Mol. Med. 69:722-724 (1991).
7. U. Cakatay. Pro-oxidant actions of a-lipoic acid and dihydrolipoic acid. Med. Hypotheses. 66:110-117 (2006).
8. A. Bliska, and L. Wlodek. Lipoic acid - the drug of the future? Pharmacol. Rep. 57: 570-577 (2005).
9. L. Packer. α-Lipoic acid: A metabolic antioxidant, which regulates NF-κ signal transduction and protects against oxidative injury. Drug Metab. Rev. 30:245-275 (1998).
10. D. Ziegler, and F. A. Gries. Alpha-lipoic acid in the treatment of diabetic peripheral and cardiac autonomic neuropathy. Diabetes. 46:S62-S66 (1997).
11. S. D. Wollin, and P. J. Jones. Alpha-lipoic acid and cardiovascular disease. J. Nutr. 133:3327-3330 (2003).
12. J. Fuchs, and R. Milbradt. Antioxidant inhibition of skin inflammation induced by reactive oxidants: Evaluation of the redox couple dihydrolipoate/lipoate. Skin Pharmacol. 7:278-284 (1994).
13. M. Podda, M. Rallis, M. G. Cuber, L. Packer, and H. Maibachl. Kinetic study of cutaneous and subcutaneous distribution following topical application of [7,8J4C] rac-cx-lipoic acid onto hairless mice. Biochem. Pharmacol. 52:627-633 (1996).
14. H. Beitner. Randomized, placebo-controlled, double blind study on the clinical efficacy of a cream containing 5% α-lipoic acid related to photoageing of facial skin. Br. J. Dermatol. 149:841-849 (2003).
15. R. H. Müller and J. S. Lucks. Medication vehicles made of solid lipid particles (solid lipid nanospheres - SLN). Eur. Patent 0605497 (1996).
16. R. H. Müller, K. Mäer, and S. Gohla. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 50:161-177 (2000).
17. R. H. Müller, and C. M. Keck. Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J. Biotech. 113:151-170 (2004).
18. E. Ugazio, R. Cavalli, and M. R. Gasco. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int. J. Pharm. 241:341-344 (2002).
19. S. A. Wissing, and R. H. Müller. Cosmetic applications for solid lipid nanoparticles (SLN). Int. J. Pharm. 254:65-68 (2003).
20. S. A. Wissing, and R. H. Müller. The influence of solid lipid nanoparticles on skin hydration and viscoelasticity - in vivo study. Int. J. Pharm. 56:67-72 (2003).
21. K. Jores, W. Mehnert, M. Drechsler, H. Bunjes, C. Johann, and K. Mäder. Investigations on the structure of solid lipid nanoparticles (SLNs) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Controlled Release. 95:217-227 (2004).
22. W. Mehnert, and K. Müder. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug. Deliv. Rev. 47:165-196 (2001).
23. V. Teeranachaideekul, E. B. Souto, V. B. Junyaprasert, and R. H. Müller. Cetyl palmitate-based NLC for topical delivery of coenzyme Q10 - development, physicochemical characterization and in vitro release studies. Eur. J. Pharm. Biopharm. 67:141-148 (2007).
24. C. Freitas, and R. H. Müller. Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase. Eur. J. Pharm. Sci. 47:125-132 (1999).
25. A. Ernst, A. Stolzing, G. Sandig, and T. Grune. Antioxidants effectively prevent oxidation-induced protein damage in OLN 93 cells. Arch. Biochem. Biophys. 421:54-60 (2004).
26. M. A. Schubert, and C. C. Müller-Goymann. Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur. J. Pharm. Biopharm. 61:77-86 (2005).
27. A. Saupe, K. C. Gordon, and T. Rades. Structural investigations on nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers by cryo-field emission scanning electron microscopy and Raman spectroscopy. Int. J. Pharm. 314:56-62 (2006).
28. W. Tiyaboonchai, W. Tungpradit, and P. Plianbangchang. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int. J. Pharm. 337:299-306 (2007).
29. H. Bunjes, K. Westesen, and M. H. J. Koch. Crystallization tendency and polymorphic transitions in triglyceride nanoparticles. Int. J. Pharm. 129:159-173 (1996).
30. A. Saupe, S. A. Wissing, A. Lenk, C. Schmidt, and R. H. Müller. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) - structural investigations on two different carrier systems. Biomedical Mater. 15: 393-402 (2005).
31. V. Jenning, A. F. Thünemann, and S. H. Gohla. Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199:167-177 (2000).
32. V. Jenning, and S. Gohla. Comparison of wax and glyceride solid lipid nanoparticles (SLN®). Int. J. Pharm. 196:219-222 (2000).
33. V. Jenning, and S. H. Gohla. Encapsulation of retinoids in solid lipid nanoparticles (SLN). J. Microencapsul. 18:149-158 (2001).
34. E. B. Souto, S. A. Wissing, C. M. Barbosa, and R. H. Müller. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 278:71-77 (2004).
35. A. Z. Mühlen, C. Schwarz, and W. Mehnert. Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism. Eur. J. Pharm. Biopharm. 45:149-155 (1998).
36. R. H. Müller, D. Rühl, S. Runge, K. Schulze-Forster, and W. Mehnert. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 14:458-462 (1997).